New Risk • May 16
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: NT$315.4m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 31% per year over the past 5 years. Market cap is less than US$10m (NT$315.4m market cap, or US$9.99m). Reported Earnings • May 07
First quarter 2026 earnings released: NT$0.52 loss per share (vs NT$0.25 loss in 1Q 2025) First quarter 2026 results: NT$0.52 loss per share (further deteriorated from NT$0.25 loss in 1Q 2025). Revenue: NT$63.4m (down 49% from 1Q 2025). Net loss: NT$12.3m (loss widened 109% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. Buy Or Sell Opportunity • Mar 26
Now 21% overvalued Over the last 90 days, the stock has fallen 5.9% to NT$16.00. The fair value is estimated to be NT$13.27, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.2% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Mar 21
Full year 2025 earnings released: NT$0.33 loss per share (vs NT$0.73 profit in FY 2024) Full year 2025 results: NT$0.33 loss per share (down from NT$0.73 profit in FY 2024). Revenue: NT$499.7m (up 11% from FY 2024). Net loss: NT$7.87m (down 145% from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance. お知らせ • Mar 05
EPS Bio Technology Corp., Annual General Meeting, May 27, 2026 EPS Bio Technology Corp., Annual General Meeting, May 27, 2026. Location: no,8, yen fa 3rd rd., baoshan township hsinchu science park, hsinchu county Taiwan Buy Or Sell Opportunity • Feb 25
Now 20% overvalued Over the last 90 days, the stock has fallen 5.0% to NT$16.20. The fair value is estimated to be NT$13.45, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Board Change • Feb 24
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 4 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Buy Or Sell Opportunity • Feb 06
Now 20% overvalued Over the last 90 days, the stock has fallen 7.9% to NT$16.35. The fair value is estimated to be NT$13.58, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Nov 06
Third quarter 2025 earnings released: EPS: NT$0.27 (vs NT$0.27 in 3Q 2024) Third quarter 2025 results: EPS: NT$0.27. Revenue: NT$130.6m (up 27% from 3Q 2024). Net income: NT$6.45m (flat on 3Q 2024). Profit margin: 4.9% (down from 6.3% in 3Q 2024). The decrease in margin was driven by higher expenses. Upcoming Dividend • Aug 21
Upcoming dividend of NT$0.67 per share Eligible shareholders must have bought the stock before 28 August 2025. Payment date: 26 September 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 3.5%. Lower than top quartile of Taiwanese dividend payers (5.3%). In line with average of industry peers (3.6%). New Risk • Aug 12
New major risk - Revenue and earnings growth Earnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 13% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$476.0m market cap, or US$15.9m). Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to NT$18.85, the stock trades at a trailing P/E ratio of 25.9x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 17% over the past three years. New Risk • Mar 20
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Payout ratio: 92% The company is paying a dividend despite having no free cash flows. Dividend yield: 2.9% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 92% Paying a dividend despite having no free cash flows. High level of non-cash earnings (41% accrual ratio). Minor Risk Market cap is less than US$100m (NT$542.6m market cap, or US$16.4m). Reported Earnings • Mar 14
Full year 2024 earnings released: EPS: NT$0.73 (vs NT$0.88 in FY 2023) Full year 2024 results: EPS: NT$0.73 (down from NT$0.88 in FY 2023). Revenue: NT$451.1m (down 4.1% from FY 2023). Net income: NT$17.3m (down 18% from FY 2023). Profit margin: 3.8% (down from 4.5% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 9% per year, which means it is tracking significantly ahead of earnings growth. お知らせ • Mar 06
EPS Bio Technology Corp., Annual General Meeting, May 28, 2025 EPS Bio Technology Corp., Annual General Meeting, May 28, 2025. Location: no,8, yen fa 3rd rd., baoshan township hsinchu science park, hsinchu county Taiwan Reported Earnings • Nov 18
Third quarter 2024 earnings released: EPS: NT$0.27 (vs NT$0.43 in 3Q 2023) Third quarter 2024 results: EPS: NT$0.27 (down from NT$0.43 in 3Q 2023). Revenue: NT$102.8m (down 12% from 3Q 2023). Net income: NT$6.44m (down 38% from 3Q 2023). Profit margin: 6.3% (down from 8.9% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. お知らせ • Oct 29
EPS Bio Technology Corp. to Report Q3, 2024 Results on Nov 06, 2024 EPS Bio Technology Corp. announced that they will report Q3, 2024 results on Nov 06, 2024 Reported Earnings • Aug 18
Second quarter 2024 earnings released: EPS: NT$0.34 (vs NT$0.18 in 2Q 2023) Second quarter 2024 results: EPS: NT$0.34 (up from NT$0.18 in 2Q 2023). Revenue: NT$133.6m (up 19% from 2Q 2023). Net income: NT$7.98m (up 91% from 2Q 2023). Profit margin: 6.0% (up from 3.7% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Aug 07
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 11% to NT$25.20. The fair value is estimated to be NT$20.75, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 14%. お知らせ • Jul 30
EPS Bio Technology Corp. to Report Q2, 2024 Results on Aug 07, 2024 EPS Bio Technology Corp. announced that they will report Q2, 2024 results on Aug 07, 2024 Upcoming Dividend • Jun 18
Upcoming dividend of NT$0.80 per share Eligible shareholders must have bought the stock before 24 June 2024. Payment date: 22 July 2024. Payout ratio is a comfortable 63% and the cash payout ratio is 82%. Trailing yield: 2.9%. Lower than top quartile of Taiwanese dividend payers (4.2%). In line with average of industry peers (3.0%). Declared Dividend • Jun 08
Dividend reduced to NT$0.80 Dividend of NT$0.80 is 18% lower than last year. Ex-date: 24th June 2024 Payment date: 22nd July 2024 Dividend yield will be 3.2%, which is lower than the industry average of 3.7%. Sustainability & Growth Dividend is not covered by earnings (119% earnings payout ratio). However, it is covered by cash flows (67% cash payout ratio). The dividend has increased by an average of 24% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 32% to bring the payout ratio under control. However, EPS has declined by 6.0% over the last 5 years so the company would need to reverse this trend. Reported Earnings • May 19
First quarter 2024 earnings released: EPS: NT$0.50 (vs NT$0.10 in 1Q 2023) First quarter 2024 results: EPS: NT$0.50 (up from NT$0.10 in 1Q 2023). Revenue: NT$97.9m (up 7.7% from 1Q 2023). Net income: NT$11.8m (up 389% from 1Q 2023). Profit margin: 12% (up from 2.7% in 1Q 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. お知らせ • May 09
EPS Bio Technology Corp. Approves Dividend for the Year 2023 The Board of EPS Bio Technology Corp. approved the proposal to distribute dividends. Date of the board of directors resolution: May 8, 2024. Year or quarter which dividends belong to: 2023. Period which dividends belong to: January 1, 2023 to December 31, 2023. Appropriations of earnings in cash dividends to shareholders (TWD per share): TWD 0.8 per share. Total amount of cash dividends to shareholders (TWD): TWD 19,040,000. Valuation Update With 7 Day Price Move • Apr 11
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to NT$24.65, the stock trades at a trailing P/E ratio of 28x. Average trailing P/E is 28x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 25% over the past three years. Reported Earnings • Mar 22
Full year 2023 earnings released: EPS: NT$0.88 (vs NT$1.07 in FY 2022) Full year 2023 results: EPS: NT$0.88 (down from NT$1.07 in FY 2022). Revenue: NT$470.2m (up 1.4% from FY 2022). Net income: NT$21.0m (down 17% from FY 2022). Profit margin: 4.5% (down from 5.5% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. お知らせ • Mar 07
EPS Bio Technology Corp., Annual General Meeting, Jun 24, 2024 EPS Bio Technology Corp., Annual General Meeting, Jun 24, 2024. Location: NO.8, R&D RD Hsinchu Science Park Hsinchu Taiwan Agenda: To consider the 2023 Business Report; to consider Audit Committee's Review Report on the 2023 Financial Statements; to consider The distribution of employees' bonus and Directors' remuneration in 2023; to consider the distribution of 2023 Earnings of cash dividend; to Adoption of the 2023 Business Report and Financial Statements; and to discuss other matters. New Risk • Nov 18
New major risk - Revenue and earnings growth Earnings have declined by 0.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.9% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (119% payout ratio). Share price has been volatile over the past 3 months (5.5% average weekly change). Profit margins are more than 30% lower than last year (4.6% net profit margin). Market cap is less than US$100m (NT$665.2m market cap, or US$21.0m). New Risk • Nov 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 95% Cash payout ratio: 95% Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Market cap is less than US$100m (NT$665.2m market cap, or US$20.8m). Valuation Update With 7 Day Price Move • Nov 13
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to NT$24.50, the stock trades at a trailing P/E ratio of 23.8x. Average trailing P/E is 27x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 32% over the past three years. Reported Earnings • Aug 11
Second quarter 2023 earnings released: EPS: NT$0.18 (vs NT$0.21 in 2Q 2022) Second quarter 2023 results: EPS: NT$0.18 (down from NT$0.21 in 2Q 2022). Revenue: NT$112.4m (up 12% from 2Q 2022). Net income: NT$4.18m (down 16% from 2Q 2022). Profit margin: 3.7% (down from 4.9% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 1% per year. お知らせ • Aug 10
EPS Bio Technology Corp. Appoints Lin, Chih-Heng as Research and Development Officer EPS Bio Technology Corp. announced the appointment of Lin, Chih-Heng, Vice President as Research and Development Officer, effective July 18, 2023. New Risk • Jul 20
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Payout ratio: 92% The company is paying a dividend despite having no free cash flows. Dividend yield: 4.9% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 92% Paying a dividend despite having no free cash flows. High level of non-cash earnings (47% accrual ratio). Minor Risk Market cap is less than US$100m (NT$478.4m market cap, or US$15.4m). Upcoming Dividend • Jun 29
Upcoming dividend of NT$0.98 per share at 4.7% yield Eligible shareholders must have bought the stock before 06 July 2023. Payment date: 04 August 2023. Payout ratio is a comfortable 46% but the company is not cash flow positive. Trailing yield: 4.7%. Lower than top quartile of Taiwanese dividend payers (5.5%). Higher than average of industry peers (3.4%). Reported Earnings • Mar 30
Full year 2022 earnings released Full year 2022 results: Revenue: NT$463.5m (down 3.5% from FY 2021). Net income: NT$25.4m (up 36% from FY 2021). Profit margin: 5.5% (up from 3.9% in FY 2021). The increase in margin was driven by lower expenses. Board Change • Jan 30
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Aug 07
Second quarter 2022 earnings released: EPS: NT$0.21 (vs NT$0.27 in 2Q 2021) Second quarter 2022 results: EPS: NT$0.21 (down from NT$0.27 in 2Q 2021). Revenue: NT$100.4m (down 16% from 2Q 2021). Net income: NT$4.95m (down 23% from 2Q 2021). Profit margin: 4.9% (down from 5.4% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. お知らせ • Aug 05
EPS Bio Technology Corp. Announces Appointment of Members of Compensation Committee EPS Bio Technology Corp. announced appointment of members of compensation committee. Name of the previous position holder: Yu-Shan Lu, Independent Director; Che-Chen Wei, Independent Director; Hsin-Yu Chung, Independent Director. Resume of the previous position holder: Yu-Shan Lu, Legal Manager of Everlight Chemical Industrial Corp.; Che-Chen Wei, Executive Assistant of Taiwan Life Insurance Co. Ltd.; Hsin-Yu Chung, Accountant of Accounting Firm. Name of the new position holder: Yu-Shan Lu, Independent Director; Che-Chen Wei, Independent Director; Hsin-Yu Chung, Independent Director. Resume of the new position holder: Yu-Shan Lu, Legal Manager of Everlight Chemical Industrial Corp.; Che-Chen Wei, Executive Assistant of Taiwan Life Insurance Co. Ltd.; Hsin-Yu Chung, Accountant of Accounting Firm. Effective date of the new members: August 4, 2022. Upcoming Dividend • Jul 05
Upcoming dividend of NT$0.70 per share Eligible shareholders must have bought the stock before 12 July 2022. Payment date: 04 August 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 6.8%. Within top quartile of Taiwanese dividend payers (6.7%). Higher than average of industry peers (3.6%). お知らせ • Jun 25
Eps Bio Technology Corp. Approves Cash Dividend for the Year 2021, Payable on August 4, 2022 EPS Bio Technology Corp. held its shareholders meeting on June 24, 2022, approved cash dividend distribution for common shares is TWD 16,660,000, (TWD 0.7 per share) for the year 2021. Ex-rights (Ex-dividend) date is July 12, 2022. Ex-rights (Ex-dividend) record date is July 18, 2022. Payment date of cash dividend distribution is August 4, 2022. Reported Earnings • May 09
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: NT$0.11 (up from NT$0.23 loss in 1Q 2021). Revenue: NT$112.7m (up 27% from 1Q 2021). Net income: NT$2.51m (up NT$7.86m from 1Q 2021). Profit margin: 2.2% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue. Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 159%. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Reported Earnings • Mar 28
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: NT$0.78 (down from NT$1.33 in FY 2020). Revenue: NT$480.3m (flat on FY 2020). Net income: NT$18.6m (down 41% from FY 2020). Profit margin: 3.9% (down from 6.6% in FY 2020). Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 159%. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Reported Earnings • Nov 07
Third quarter 2021 earnings released: EPS NT$0.16 (vs NT$0.49 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: NT$125.5m (up 14% from 3Q 2020). Net income: NT$3.79m (down 68% from 3Q 2020). Profit margin: 3.0% (down from 11% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Reported Earnings • Aug 09
Second quarter 2021 earnings released: EPS NT$0.27 (vs NT$0.59 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$119.4m (down 17% from 2Q 2020). Net income: NT$6.46m (down 54% from 2Q 2020). Profit margin: 5.4% (down from 9.8% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 4% per year. Upcoming Dividend • Jul 15
Upcoming dividend of NT$1.20 per share Eligible shareholders must have bought the stock before 21 July 2021. Payment date: 13 August 2021. Trailing yield: 5.9%. Within top quartile of Taiwanese dividend payers (5.0%). Higher than average of industry peers (2.9%). Reported Earnings • May 09
First quarter 2021 earnings released: NT$0.22 loss per share (vs NT$0.18 profit in 1Q 2020) The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2021 results: Revenue: NT$88.5m (down 17% from 1Q 2020). Net loss: NT$5.35m (down 225% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. お知らせ • May 07
Board of Directors Approves Proposal to Distribute Dividends EPS Bio Technology Corp. announced cash dividends of NTD 1.2 per share or NTD 28,560,000. お知らせ • Mar 19
EPS Bio Technology Corp., Annual General Meeting, Jun 28, 2021 EPS Bio Technology Corp., Annual General Meeting, Jun 28, 2021. Reported Earnings • Mar 18
Full year 2020 earnings released: EPS NT$1.33 (vs NT$0.78 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$477.6m (up 4.0% from FY 2019). Net income: NT$31.7m (up 72% from FY 2019). Profit margin: 6.6% (up from 4.0% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 09
Third quarter 2020 earnings released: EPS NT$0.49 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$109.6m (up 7.1% from 3Q 2019). Net income: NT$11.7m (up 84% from 3Q 2019). Profit margin: 11% (up from 6.2% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Oct 30
New 90-day low: NT$20.00 The company is down 6.0% from its price of NT$21.25 on 31 July 2020. The Taiwanese market is flat over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 8.0% over the same period. 
